Cancer-fighting implant shows promise in treating tumors

By Stephen Beech

A new high-tech implant has shown "promise" in fighting some of the deadliest forms of cancer.

The cancer-fighting device safely triggers "potent" immune responses against hard-to-treat cancers, including metastatic melanoma, and pancreatic and colorectal tumors, say American scientists.

A team of researchers from the Rice Biotech Launch Pad at Rice University in Houston developed the implantable “cytokine factory”.

They explained how an immunoprotective device near the tumor microenvironment containing cells engineered to locally release the protein interleukin-12 (IL-12) successfully induces the recruitment of specialized immune cells called precursor exhausted T cells (Tpex cells).

The Tpex cell recruitment results in a large, durable population of tumor-targeting T cells, according to a study published in The Journal of ImmunoTherapy of Cancer.

The IL-12 cytokine factories, combined with checkpoint inhibitors, successfully eliminated local and distal tumors in preclinical models of metastatic melanoma and colorectal and pancreatic cancers.

The IL-12 cytokine factory also demonstrated safety in both mice and non-human primates, according to the findings.

The research team said the study will serve as the foundation for an investigational new drug application (IND) with the U.S. FDA in early 2026.

They also plan to launch an emerging biotech company based on the ground-breaking IL-12 cytokine factory technology.

Study senior corresponding author Professor Omid Veiseh, faculty director of the Rice Biotech Launch Pad, said: “We designed the IL-12 cytokine factory to enhance immunotherapy approaches while minimizing toxicity, a critical need in the treatment of particularly aggressive cancers.

“IL-12 is particularly impactful compared to other cytokines, as our research demonstrates that other cytokines primarily recruit homogeneous T cell populations and show reduced efficacy over time, while IL-12 generates a more robust antitumor response by recruiting a more durable, broader repertoire of tumor-targeting T cells.

“We are hopeful that this technology will significantly impact the lives of cancer patients by enhancing the efficacy of immunotherapy approaches in the clinic.”

Dr. Nathan Reticker-Flynn, of Stanford University, said: “Harnessing the cellular immune system to target solid tumors is a common but often fraught approach to fighting cancer as the associated challenge of efficacious treatment without toxicity remains elusive.

“Our study demonstrates not only the efficacy of this technology in preclinical models but also its safety profile, which is a critical aspect as we move toward clinical trials."

He added: "This research represents an important step forward in the quest to provide more effective treatments for patients battling metastatic cancers.”